FR14C0082I2 - NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS - Google Patents

NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS

Info

Publication number
FR14C0082I2
FR14C0082I2 FR14C0082C FR14C0082C FR14C0082I2 FR 14C0082 I2 FR14C0082 I2 FR 14C0082I2 FR 14C0082 C FR14C0082 C FR 14C0082C FR 14C0082 C FR14C0082 C FR 14C0082C FR 14C0082 I2 FR14C0082 I2 FR 14C0082I2
Authority
FR
France
Prior art keywords
phosphoramidate prodrugs
nucleoside phosphoramidate
nucleoside
prodrugs
phosphoramidate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR14C0082C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Pharmasset LLC
Original Assignee
Gilead Pharmasset LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39808855&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR14C0082(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Pharmasset LLC filed Critical Gilead Pharmasset LLC
Publication of FR14C0082I1 publication Critical patent/FR14C0082I1/fr
Application granted granted Critical
Publication of FR14C0082I2 publication Critical patent/FR14C0082I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR14C0082C 2007-03-30 2014-11-19 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS Active FR14C0082I2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US90931507P 2007-03-30 2007-03-30
US98230907P 2007-10-24 2007-10-24
US12/053,015 US7964580B2 (en) 2007-03-30 2008-03-21 Nucleoside phosphoramidate prodrugs
PCT/US2008/058183 WO2008121634A2 (en) 2007-03-30 2008-03-26 Nucleoside phosphoramidate prodrugs

Publications (2)

Publication Number Publication Date
FR14C0082I1 FR14C0082I1 (en) 2014-12-26
FR14C0082I2 true FR14C0082I2 (en) 2015-11-13

Family

ID=39808855

Family Applications (1)

Application Number Title Priority Date Filing Date
FR14C0082C Active FR14C0082I2 (en) 2007-03-30 2014-11-19 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS

Country Status (36)

Country Link
US (11) US7964580B2 (en)
EP (7) EP2933260A1 (en)
JP (8) JP5318085B2 (en)
KR (3) KR101527701B1 (en)
CN (8) CN116731099A (en)
AR (1) AR066898A1 (en)
AU (1) AU2008232827C1 (en)
BR (2) BRPI0809654A2 (en)
CA (1) CA2682230C (en)
CL (1) CL2008000902A1 (en)
CO (1) CO6260023A2 (en)
CY (2) CY1115488T1 (en)
DE (1) DE202008018643U1 (en)
DK (1) DK2203462T3 (en)
ES (3) ES2492470T3 (en)
FR (1) FR14C0082I2 (en)
HK (2) HK1206034A1 (en)
HR (1) HRP20140667T1 (en)
HU (1) HUS1400059I1 (en)
IL (3) IL201239A (en)
LT (1) LTC2203462I2 (en)
LU (1) LU92600I2 (en)
MX (1) MX2009010401A (en)
MY (1) MY147409A (en)
NL (1) NL300704I2 (en)
NO (1) NO2014029I1 (en)
NZ (2) NZ579880A (en)
PH (1) PH12014502771A1 (en)
PL (3) PL2203462T3 (en)
PT (3) PT2203462E (en)
RU (4) RU2651892C2 (en)
SG (2) SG2014011704A (en)
SI (3) SI2801580T1 (en)
TW (1) TWI357332B (en)
WO (1) WO2008121634A2 (en)
ZA (2) ZA200906647B (en)

Families Citing this family (249)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1736478B1 (en) 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Methods and compositions for treating flaviviruses and pestiviruses
EP1539188B1 (en) 2001-01-22 2015-01-07 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
MXPA05005192A (en) 2002-11-15 2005-09-08 Idenix Cayman Ltd 2aCOE-BRANCHED NUCLEOSIDES AND FLAVIVIRIDAE.
CN100503628C (en) 2003-05-30 2009-06-24 法莫赛特股份有限公司 Modified fluorinated nucleoside analogues
CA2589935A1 (en) 2004-12-09 2006-06-15 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
TW201334784A (en) 2008-04-23 2013-09-01 Gilead Sciences Inc 1'-substituted carba-nucleoside analogs for antiviral treatment
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010068708A2 (en) 2008-12-09 2010-06-17 Rfs Pharma, Llc 3'-azido purine nucleotide prodrugs for treatment of viral infections
TW201031675A (en) 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
US8551973B2 (en) * 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
AU2009329867B2 (en) 2008-12-23 2015-01-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
WO2010091386A2 (en) * 2009-02-06 2010-08-12 Rfs Pharma, Llc Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
JP2012521359A (en) * 2009-03-20 2012-09-13 アリオス バイオファーマ インク． Substituted nucleoside and nucleotide analogs
EP2857394A1 (en) 2009-05-13 2015-04-08 Gilead Pharmasset LLC Antiviral compounds
AU2014274548B2 (en) * 2009-05-20 2016-02-04 Gilead Pharmasset Llc N- [ (2 ' R) -2 ' -deoxy-2 ' -fluoro-2 ' -methyl-p-phenyl-5 ' -uridylyl] -L-alanine 1-methylethyl ester and process for its production
TWI576352B (en) * 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
AU2016200676B2 (en) * 2009-05-20 2017-06-01 Gilead Pharmasset Llc N-[(2'R)-2 '-deoxy-2'-fluoro-2'-methyl-p-phenyl-5'-uridylyl] -L-alanine 1-methylethyl ester and process for its production
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
PT2480559E (en) 2009-09-21 2013-10-02 Gilead Sciences Inc Processes and intermediates for the preparation of 1'-cyano-carbanucleoside analogs
BR112012007122A2 (en) * 2009-09-29 2016-07-12 Janssen Products Lp nucleoside phosphoramidate derivatives
EA201200650A1 (en) 2009-10-30 2012-12-28 Бёрингер Ингельхайм Интернациональ Гмбх COMBINED TREATMENTS OF HEPATITIS C VIRUS, INCLUDING BI201335, INTERFERON-ALPHA AND RIBAVIRIN COURSES
NZ599963A (en) * 2009-12-18 2014-02-28 Boehringer Ingelheim Int Hcv combination therapy
HUE026235T2 (en) * 2010-03-31 2016-06-28 Gilead Pharmasset Llc Crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1-(2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
TW201136945A (en) 2010-03-31 2011-11-01 Pharmasset Inc Purine nucleoside phosphoramidate
US9023788B2 (en) 2010-04-20 2015-05-05 New York University Methods compounds and pharmaceutical compositions for treating anxiety and mood disorders
MA34471B1 (en) * 2010-07-19 2013-08-01 Gilead Sciences Inc METHODS FOR PREPARING PURITY PHOSPHORAMIDATE PRODRUGS IN THE DIASTEROMERIC PLAN
UA111163C2 (en) 2010-07-22 2016-04-11 Гайлід Сайєнсіз, Інк. METHODS AND COMPOUNDS FOR THE TREATMENT OF Viral Infections of PARAMYXOVIRIDAE
WO2012040127A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
US8877731B2 (en) 2010-09-22 2014-11-04 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
TW201242974A (en) 2010-11-30 2012-11-01 Gilead Pharmasset Llc Compounds
US9095599B2 (en) 2011-01-03 2015-08-04 Nanjing Molecular Research, Inc. O-(substituted benzyl) phosphoramidate compounds and therapeutic use
DK2681227T3 (en) 2011-03-01 2016-02-22 Nucana Biomed Ltd PHOSPHORAMIDATE DERIVATIVES OF 5-FLUOR-2'-DEOXYURIDINE FOR USE IN CANCER TREATMENT
WO2012125900A1 (en) 2011-03-16 2012-09-20 Enanta Pharmaceuticals, Inc. 2'-allene-substituted nucleoside derivatives
WO2012154321A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
KR20140019832A (en) * 2011-04-13 2014-02-17 길리애드 사이언시즈, 인코포레이티드 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment
US20140212382A1 (en) * 2011-05-19 2014-07-31 Emory University Purine monophosphate prodrugs for treatment of viral infections
US20130018011A1 (en) * 2011-06-10 2013-01-17 Hassan Javanbakht Method of treating dengue fever
WO2013013009A2 (en) * 2011-07-19 2013-01-24 Nanjing Molecular Research, Inc. 2',3'-DIDEOXY-2'-α-FLUORO-2'-β-C-METHYLNUCLEOSIDES AND PRODRUGS THEREOF
US9403863B2 (en) 2011-09-12 2016-08-02 Idenix Pharmaceuticals Llc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
PL2709613T5 (en) 2011-09-16 2020-12-14 Gilead Pharmasset Llc Methods for treating hcv
IN2014CN03043A (en) 2011-09-30 2015-07-03 Univ Tufts
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN104023726A (en) * 2011-10-21 2014-09-03 艾伯维公司 Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
UY34402A (en) 2011-10-21 2013-05-31 Abbvie Inc METHODS FOR HCV TREATMENT
CA2853495A1 (en) 2011-10-31 2013-05-10 Gilead Pharmasset Llc Methods and compositions for treating hepatitis c virus
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
BR112014012739A8 (en) 2011-11-29 2017-06-20 Gilead Pharmasset Llc compositions and methods for the treatment of hepatitis c virus
CN104185420B (en) 2011-11-30 2017-06-09 埃默里大学 Antiviral JAK inhibitor for treating or preventing retrovirus and other virus infection
JP5982007B2 (en) * 2011-12-20 2016-08-31 リボサイエンス・エルエルシー 2 ', 4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
KR101687084B1 (en) * 2011-12-20 2016-12-15 리보사이언스 엘엘씨 4'-azido, 3'-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
EP2794627B1 (en) * 2011-12-22 2018-09-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CA2857339C (en) * 2011-12-29 2015-11-17 Abbvie Inc. Solid compositions comprising an hcv inhibitor
US9303652B2 (en) 2012-01-05 2016-04-05 Archipelago Group Llc Electric blower operable to provide combustion air to a fire
MX2014009850A (en) 2012-02-14 2015-03-10 Univ Georgia Spiro [2.4]heptanes for treatment of flaviviridae infections.
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
NZ631601A (en) 2012-03-21 2016-06-24 Alios Biopharma Inc Solid forms of a thiophosphoramidate nucleotide prodrug
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
WO2013173759A2 (en) * 2012-05-17 2013-11-21 Enanta Pharmaceuticals, Inc. Macrocyclic nucleoside phosphoramidate derivatives
US9109001B2 (en) 2012-05-22 2015-08-18 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphoramidate prodrugs for HCV infection
JP6165848B2 (en) * 2012-05-22 2017-07-19 イデニク ファーマシューティカルズ エルエルシー D-amino acid compounds for liver disease
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
CA2871547C (en) 2012-05-25 2021-05-25 Janssen R&D Ireland Uracyl spirooxetane nucleosides
US9206412B2 (en) * 2012-05-31 2015-12-08 Colorado State University Research Foundation Thioxothiazolidine inhibitors
CN104640444B (en) * 2012-06-16 2016-12-14 河南美泰宝生物制药有限公司 Double liver target phosphoramidates and aminophosphonic acid ester prodrugs
KR20150027155A (en) 2012-07-03 2015-03-11 브리스톨-마이어스 스큅 컴퍼니 Process for preparing diastereomerically enriched phosphoramidate derivatives of nucleoside compounds for treatment of viral infections
WO2014047117A1 (en) 2012-09-18 2014-03-27 Bristol-Myers Squibb Company Process for preparing phosphoramidate derivatives of nucleoside compounds for treatment of viral infections
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
WO2014052896A1 (en) 2012-09-28 2014-04-03 Tufts University Uridine diphosphate derivatives, prodrugs, compositions and uses thereof
AU2013329521B2 (en) 2012-10-08 2018-04-19 Centre National De La Recherche Scientifique 2'-chloro nucleoside analogs for HCV infection
EP2909222B1 (en) 2012-10-22 2021-05-26 Idenix Pharmaceuticals LLC 2',4'-bridged nucleosides for hcv infection
EP2920195A1 (en) 2012-11-14 2015-09-23 IDENIX Pharmaceuticals, Inc. D-alanine ester of rp-nucleoside analog
WO2014078436A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of sp-nucleoside analog
JP2016506371A (en) * 2012-11-16 2016-03-03 ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド Methods for preparing nucleoside prodrugs
WO2014099941A1 (en) * 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
AU2013361200A1 (en) 2012-12-21 2015-07-23 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
SG10201706949VA (en) 2013-01-31 2017-09-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US10034893B2 (en) * 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
WO2014137929A1 (en) 2013-03-04 2014-09-12 Gilead Pharmasset Llc Methods for treating hepatitis c virus
WO2014137926A1 (en) * 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
CA2899763C (en) * 2013-03-08 2020-03-10 Nanjing Sanhome Pharmaceutical Co., Ltd. Nucleoside phosphoramidate compound and use thereof
US20140271547A1 (en) 2013-03-13 2014-09-18 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
DK2968385T3 (en) 2013-03-13 2018-09-03 Univ Tufts URIDINNUCLEOSIDE DERIVATIVES, COMPOSITIONS AND PROCEDURES FOR USING THEREOF
AR095442A1 (en) 2013-03-13 2015-10-14 Univ Tufts URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE
RU2534613C2 (en) * 2013-03-22 2014-11-27 Александр Васильевич Иващенко Alkyl2-{[(2r,3s,5r)-5-(4-amino-2-oxo-2h-pyrimidine-1-yl)- -hydroxy- tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-proptonates, nucleoside inhibitors of rna-polymerase hcv ns5b, methods for producing and using them
US9187515B2 (en) 2013-04-01 2015-11-17 Idenix Pharmaceuticals Llc 2′,4′-fluoro nucleosides for the treatment of HCV
BR112015025766A2 (en) 2013-04-12 2017-10-17 Achillion Pharmaceuticals Inc highly active nucleoside derivative for the treatment of hcv
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
MX2015015782A (en) 2013-05-16 2016-06-02 Riboscience Llc 4'-fluor0-2'-methyl substituted nucleoside derivatives.
US20140357595A1 (en) 2013-06-04 2014-12-04 Gilead Pharmasset Llc Methods of preventing and treating recurrence of a hepatitis c virus infection in a subject after the subject has received a liver transplant
WO2014197578A1 (en) * 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv
CN104231023B (en) * 2013-06-06 2019-02-05 南京汇诚制药有限公司 Tricyclic fused heterocycle nucleoside phosphoramidate compound, preparation method and application
JP6453322B2 (en) 2013-06-26 2019-01-16 アリオス バイオファーマ インク． Substituted nucleosides, substituted nucleotides and analogs thereof
EP3027636B1 (en) 2013-08-01 2022-01-05 Idenix Pharmaceuticals LLC D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
MX2016002185A (en) 2013-08-27 2016-06-06 Gilead Pharmasset Llc Combination formulation of two antiviral compounds.
UA117375C2 (en) 2013-09-04 2018-07-25 Медівір Аб Hcv polymerase inhibitors
WO2015038596A1 (en) 2013-09-11 2015-03-19 Emory University Nucleotide and nucleoside compositions and uses related thereto
WO2015042447A1 (en) 2013-09-20 2015-03-26 Isis Pharmaceuticals, Inc. Targeted therapeutic nucleosides and their use
CN104447923B (en) * 2013-09-23 2018-03-30 中国药科大学 Methyl nucleoside derivatives of 2 ' deoxidation, 2 ' fluorine 2 ' and preparation method thereof and the purposes in pharmacy
US8889701B1 (en) 2013-10-11 2014-11-18 Alla Chem, Llc Substituted (S)-(2R,3R,5R)-3-hydroxy-(5-pyrimidin-1-yl)tetrahydrofuran-2-ylmethyl aryl phosphoramidate
KR102314960B1 (en) 2013-10-11 2021-10-19 얀센 바이오파마, 인코퍼레이트. Substituted nucleosides, nucleotides and analogs thereof
WO2015056213A1 (en) 2013-10-17 2015-04-23 Medivir Ab Hcv polymerase inhibitors
WO2015061683A1 (en) * 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
CN104650171A (en) * 2013-11-25 2015-05-27 天津市汉康医药生物技术有限公司 Sofosbuvir sesquihydrate compound
US20170198005A1 (en) * 2013-11-27 2017-07-13 Idenix Pharmaceuticals Llc 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
RU2553996C1 (en) * 2013-11-27 2015-06-20 Андрей Александрович Иващенко Substituted (2r,3r,5r)-3-hydroxy-(5-pyrimidin-1-yl)tetrahydrofuran-2-ylmethyl aryl phosphoramidates
US20150150897A1 (en) 2013-12-02 2015-06-04 Gilead Pharmasset Llc Methods of treating hepatitis c virus infection in subjects with cirrhosis
TW201609785A (en) 2013-12-23 2016-03-16 吉李德製藥公司 Solid forms of an antiviral compound
US10100075B2 (en) 2013-12-23 2018-10-16 Mylan Laboratories Limited Process for the preparation of sofosbuvir
CN104761604A (en) * 2014-01-02 2015-07-08 江苏豪森药业股份有限公司 Uridine monophosphate analogue, and preparation method and applications thereof
WO2015126995A1 (en) 2014-02-20 2015-08-27 Ratiopharm Gmbh Solid state forms of sofosbuvir
CN103804446A (en) * 2014-02-27 2014-05-21 苏州东南药业股份有限公司 Preparation method of 3,5-dibenzoyl-2-deoxy-2-fluoro-2-methyl-D-ribo-gamma-lactone
EP3113763A1 (en) * 2014-03-05 2017-01-11 Idenix Pharmaceuticals LLC Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv
WO2015134560A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid forms of a flaviviridae virus inhibitor compound and salts thereof
US20170135990A1 (en) 2014-03-05 2017-05-18 Idenix Pharmaceuticals Llc Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
CZ307789B6 (en) 2014-04-15 2019-05-09 Zentiva, K.S. Method of producing biologically active phosphoramidate medicaments
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
CN106536538A (en) * 2014-04-24 2017-03-22 共晶制药股份有限公司 2'-disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
TWI721947B (en) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 Solid forms of an antiviral compound
EP3154526B1 (en) 2014-06-13 2019-03-06 ratiopharm GmbH Solid state forms of sofosbuvir
US20170112867A1 (en) 2014-06-23 2017-04-27 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical combinations of sofosbuvir and ribavirin
WO2015197535A1 (en) 2014-06-23 2015-12-30 Sanovel Ilac Sanayi Ve Ticaret A.S. Modified release pharmaceutical compositions of sofosbuvir and ribavirin
US20170151272A1 (en) 2014-06-23 2017-06-01 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A novel pharmaceutical composition of sofosbuvir and ribavirin
CZ2014502A3 (en) 2014-07-17 2016-01-27 Zentiva, K.S. Sofosbuvir novel form and process for preparing thereof
CN105315319B (en) * 2014-07-30 2020-11-20 南京圣和药业股份有限公司 Hepatitis C virus inhibitor and application thereof
US20170218007A1 (en) 2014-08-01 2017-08-03 Lupin Limited A process for the preparation of nucleoside phosphoramidate
WO2016023522A2 (en) * 2014-08-15 2016-02-18 Merck Sharp & Dohme Corp. Substituted phosphoramidate compounds and uses thereof
WO2016033164A1 (en) 2014-08-26 2016-03-03 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
WO2016035006A1 (en) * 2014-09-01 2016-03-10 Dr. Reddy’S Laboratories Limited Novel nucleotide analogs, process for the preparation of sofosbuvir and its analogs, novel forms of sofosbuvir and solid dispersion of sofosbuvir
WO2016038542A2 (en) 2014-09-10 2016-03-17 Mylan Laboratories Limited Polymorphic forms of sofosbuvir
WO2016042576A1 (en) 2014-09-16 2016-03-24 Cadila Healthcare Limited Co-crystal of sofosbuvir and amino acid and process for preparation thereof
US10251903B2 (en) * 2014-10-20 2019-04-09 Merck Sharp & Dohme Corp. Process for making nucleoside phosphoramidate compounds
TWI740546B (en) 2014-10-29 2021-09-21 美商基利科學股份有限公司 Methods for the preparation of ribosides
CA2966033A1 (en) * 2014-10-31 2016-05-06 Cocrystal Pharma, Inc. 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
US9718851B2 (en) 2014-11-06 2017-08-01 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
WO2016074596A1 (en) * 2014-11-10 2016-05-19 南京曼杰生物科技有限公司 Nucleoside phosphoramidate derivative and application thereof
RU2567854C1 (en) * 2014-11-11 2015-11-10 Александр Васильевич Иващенко Nucleoside inhibitors of rna-polymerase hcv ns5b, methods for production and use thereof
CN105294795B (en) * 2014-11-20 2019-01-15 南京曼杰生物科技有限公司 Nucleoside phosphoramidate derivative and its application
US9732110B2 (en) 2014-12-05 2017-08-15 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
WO2016099982A2 (en) 2014-12-15 2016-06-23 Emory University Phosphoramidates for the treatment of hepatitis b virus
CN107427495A (en) 2015-02-13 2017-12-01 桑多斯股份公司 Include Lei Dipawei and Suo Feibuwei pharmaceutical composition
ITUB20150109A1 (en) * 2015-03-05 2016-09-05 Hc Pharma Ag USEFUL COMPOUNDS FOR THE TREATMENT OF HEPATITIS C
US9828410B2 (en) * 2015-03-06 2017-11-28 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
US10407456B2 (en) 2015-03-26 2019-09-10 Quimica Sintetica, S.A. Nucleoside phosphoramidates useful for the treatment of viral infections and preparation thereof
ITUB20152109A1 (en) * 2015-07-13 2017-01-13 Quim Sintetica S A PHOSPHORAMIDATE NUCLEOSIDES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS AND THEIR PREPARATION
CN106146588A (en) * 2015-03-26 2016-11-23 常州制药厂有限公司 A kind of preparation method of Suo Feibuwei
CN106188192B (en) * 2015-04-29 2019-09-10 刘沛 Nucleosides phosphoramidic acid/the phosphate derivatives and its medical usage of the amino-acid ester containing D-
CN106188193A (en) * 2015-05-07 2016-12-07 苏州旺山旺水生物医药有限公司 (2`R)-2`-deoxidation-2`-halo-2`-MU glycoside derivates, Preparation Method And The Use
CN104829672B (en) * 2015-05-19 2018-03-13 江苏福瑞生物医药有限公司 A kind of synthetic method of pharmaceutical intermediate
WO2016189443A2 (en) * 2015-05-23 2016-12-01 Virupaksha Organics Limited Solid forms of nucleoside phosphoramidate
EP3303360A1 (en) 2015-05-26 2018-04-11 Sandoz AG Selective process for synthesis of nucleoside phosphoramidates
WO2016196735A2 (en) 2015-06-03 2016-12-08 Teva Pharmaceuticals International Gmbh Improved processes for the preparation of sofosbuvir and intermediates thereof
CZ2015443A3 (en) 2015-06-26 2017-01-04 Zentiva, K.S. Sofosbuvir pharmaceutical formulation
EP3331895B1 (en) 2015-08-06 2020-07-29 Chimerix, Inc. Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
EP3133062A1 (en) 2015-08-19 2017-02-22 Zaklady Farmaceutyczne Polpharma SA Process for the preparation of a pharmaceutical agent
WO2017029408A1 (en) 2015-08-20 2017-02-23 Ratiopharm Gmbh Solid state forms of sofosbuvir
CN105061535A (en) * 2015-09-02 2015-11-18 江苏科本医药化学有限公司 Synthetic method of sofosbuvir intermediate
EP3344642A1 (en) 2015-09-02 2018-07-11 AbbVie Inc. Anti-viral tetrahydrofurane derivatives
EP3785717B1 (en) 2015-09-16 2022-01-05 Gilead Sciences, Inc. Methods for treating coronaviridae infections
WO2017077552A1 (en) 2015-11-03 2017-05-11 Mylan Laboratories Limited Process for the preparation of sofosbuvir
CN106674320B (en) * 2015-11-06 2020-04-21 博瑞生物医药（苏州）股份有限公司 HCV (hepatitis C virus) treatment medicine
CN106674319B (en) * 2015-11-06 2020-04-21 博瑞生物医药（苏州）股份有限公司 Compound for treating hepatitis C
CN106674318B (en) * 2015-11-06 2020-04-21 博瑞生物医药（苏州）股份有限公司 NS5B polymerase inhibitor
AU2016355429B2 (en) 2015-11-16 2021-05-06 Cerecor, Inc. Nucleic acid prodrugs
WO2017093973A1 (en) * 2015-12-02 2017-06-08 Sun Pharmaceutical Industries Limited Process for the preparation of pure sofosbuvir
ITUB20161079A1 (en) 2016-02-25 2017-08-25 Hc Pharma Ag PROCEDURE FOR THE PREPARATION OF SOFOSBUVIR
EP3430023A1 (en) 2016-03-17 2019-01-23 Mylan Laboratories, Limited Polymorphic forms of sofosbuvir
CN107226831A (en) * 2016-03-25 2017-10-03 江苏天士力帝益药业有限公司 Uridine phosphamide prodrug, its preparation method and its in application pharmaceutically
WO2017184670A2 (en) 2016-04-22 2017-10-26 Gilead Sciences, Inc. Methods for treating zika virus infections
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2017192665A1 (en) 2016-05-03 2017-11-09 The Regents Of The University Of California Inhibitors of ires-mediated protein synthesis
CZ2016257A3 (en) 2016-05-05 2017-11-15 Zentiva, K.S. The amorphous form of sofosbuvir, the method of its preparation and its stabilization
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109562113A (en) 2016-05-10 2019-04-02 C4医药公司 Loop coil degron body for target protein degradation
BR112018073858A2 (en) 2016-05-27 2019-02-26 Gilead Sciences, Inc. methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors
BR102017011025A2 (en) 2016-06-02 2017-12-19 Gilead Pharmasset Llc FORMULATION OF COMBINATION OF THREE ANTIVIRAL COMPOUNDS
CN107501247A (en) * 2016-06-14 2017-12-22 安徽贝克联合制药有限公司 A kind of preparation method of uridine analog derivative
EP3471739A4 (en) * 2016-06-20 2020-02-26 Merck Sharp & Dohme Corp. Use of cyclic phosphate substituted nucleoside derivatives for the treatment of viral diseases
CA3029315A1 (en) 2016-06-24 2017-12-28 Emory University Phosphoramidates for the treatment of hepatitis b virus
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
US10239910B2 (en) * 2016-07-20 2019-03-26 Optimus Drugs (P) Limited Process for the preparation of sofosbuvir
US20180030080A1 (en) * 2016-07-28 2018-02-01 Alexandre Vasilievich Ivachtchenko Phosphoramidate nucleoside prodrug for treating viral diseases and cancer, processes for their preparation and their use
US20190185507A1 (en) * 2016-08-19 2019-06-20 Sandoz Ag Sofosbuvir Derivatives for the Treatment of Hepatitis C
EP4088725A1 (en) 2016-09-07 2022-11-16 ATEA Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for the treatment of a virus from the picornaviridae family
WO2018078536A1 (en) 2016-10-26 2018-05-03 Lupin Limited Stable solid dispersion of sofosbuvir and process for preparation thereof
MX2019007585A (en) 2016-12-22 2019-09-09 Merck Sharp & Dohme Antiviral aliphatic ester prodrugs of tenofovir.
WO2018134343A1 (en) 2017-01-19 2018-07-26 Sandoz Ag Synthesis of phosphoramidates
EP3571183B1 (en) 2017-01-20 2024-03-06 The Regents of the University of California 3-(phenyl)-2-(aminomethyl)-1-phenyl-2-propen-1-one derivatives as inhibitors of the n-terminal domain of the androgen receptor for treating prostate cancer
JP7066728B2 (en) 2017-02-01 2022-05-13 アテア ファーマシューティカルズ， インコーポレイテッド Nucleotide hemi sulfate for the treatment of hepatitis C virus
RU2659388C1 (en) * 2017-02-28 2018-07-02 Васильевич Иващенко Александр Nucleotides including n-[(s)-1-cyclobutoxycarbonyl]phosphoramidate fragment, their analogs and their application
RU2644156C1 (en) * 2017-02-28 2018-02-08 Александр Васильевич Иващенко Prodrug of polymerase ns5b hcv inhibitor, method for its preparation and application
RU2650610C1 (en) * 2017-02-28 2018-04-16 Васильевич Иващенко Александр Antiviral composition and method of its application
ES2961460T3 (en) 2017-03-14 2024-03-12 Gilead Sciences Inc Methods to treat feline coronavirus infections
WO2018204198A1 (en) 2017-05-01 2018-11-08 Gilead Sciences, Inc. Crystalline forms of (s) 2 ethylbutyl 2 (((s) (((2r,3s,4r,5r) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
RU2656228C9 (en) * 2017-06-13 2019-04-16 Олег Ростиславович Михайлов WEAKLY CRYSTALLISED β-MODIFICATION OF (S)-ISOPROPYL 2-((S)-(((2R,3R,4R,5R)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-(2H)-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YL)METHOXY)-(PHENOXY)PHOSPHORYLAMINO)PROPANOATE, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION BASED THEREON
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
US10675296B2 (en) 2017-07-11 2020-06-09 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
EP3661944A1 (en) 2017-08-03 2020-06-10 Sandoz AG Sofosbuvir hydrate
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
WO2019060740A1 (en) * 2017-09-21 2019-03-28 Riboscience Llc 4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
EP3684771A1 (en) 2017-09-21 2020-07-29 Chimerix, Inc. MORPHIC FORMS OF 4-AMINO-7-(3,4-DIHYDROXY-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-2-METHYL-7H-PYRROLO[2,3-d]PYRIMIDINE-5-CARBOXAMIDE AND USES THEREOF
WO2019136389A1 (en) * 2018-01-05 2019-07-11 Cerecor, Inc. Nucleotide prodrugs
JP2021521118A (en) 2018-04-10 2021-08-26 アテア ファーマシューティカルズ， インコーポレイテッド Treatment of HCV-infected patients with cirrhosis
NL2021049B1 (en) 2018-06-04 2019-12-11 Academisch Ziekenhuis Leiden Use of 6'-fluoro-neplanocin a derivatives against chikungunya virus
EP3813841A4 (en) 2018-06-29 2022-03-09 The Regents Of The University Of California New molecular tweezers against neurological disorders and viral infections
AU2019310595B2 (en) 2018-07-27 2022-11-24 1200 Pharma Llc CDK inhibitors and uses thereof
KR102130253B1 (en) 2018-09-17 2020-07-03 영진약품 주식회사 Novel thiazole derivatives and pharmaceutically acceptable salts thereof
SG11202110272SA (en) 2019-03-25 2021-10-28 California Inst Of Techn Prmt5 inhibitors and uses thereof
JP2022533398A (en) 2019-05-20 2022-07-22 カリフォルニア インスティチュート オブ テクノロジー KRAS G12C inhibitors and uses thereof
US11660307B2 (en) 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021183750A2 (en) 2020-03-12 2021-09-16 Gilead Sciences, Inc. Methods of preparing 1'-cyano nucleosides
AU2021244195A1 (en) 2020-03-22 2022-09-15 Inspirmed Corp. Composition of antiviral agent for use in prophylactic or post-exposure treatment of infectious or respiratory diseases
WO2021202669A2 (en) 2020-04-01 2021-10-07 Reyoung Corporation Nucleoside and nucleotide conjugate compounds and uses thereof
WO2021207049A1 (en) 2020-04-06 2021-10-14 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CN111467363A (en) * 2020-04-07 2020-07-31 中国科学院深圳先进技术研究院 Application of sofosbuvir in preparation of medicine for preventing and treating coronavirus
EP4157272A1 (en) 2020-05-29 2023-04-05 Gilead Sciences, Inc. Remdesivir treatment methods
MX2022016405A (en) 2020-06-24 2023-01-30 Gilead Sciences Inc 1'-cyano nucleoside analogs and uses thereof.
WO2021263072A1 (en) 2020-06-25 2021-12-30 Dana-Farber Cancer Institute, Inc. Methods of treating disease
KR20220005991A (en) 2020-07-07 2022-01-14 (주)아이랩 A novel tnf activity inhibitor compound and its pharmaceutically acceptable salt
WO2022035805A1 (en) 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
EP4192811A1 (en) 2020-08-10 2023-06-14 Dana-Farber Cancer Institute, Inc. Substituted 3-amino-4-methylbenzenesulfonamides as small molecule inhibitors of ubiquitin-specific protease 28
EP4192838A1 (en) 2020-08-10 2023-06-14 Dana-Farber Cancer Institute, Inc. Fused tricyclic pyrimidine-thieno-pyridine small molecule inhibitors of ubiquitin-specific protease 28
JP2023540225A (en) 2020-08-27 2023-09-22 ギリアード サイエンシーズ， インコーポレイテッド Compounds and methods for the treatment of viral infections
EP4225282A1 (en) * 2020-10-09 2023-08-16 ATEA Pharmaceuticals, Inc. Niran interfering drugs for sars-cov-2 mutant therapy
US20230399304A1 (en) 2020-10-23 2023-12-14 Dana-Farber Cancer Institute, Inc. Covalent inhibitors of creatine kinase (ck) and uses thereof for treating and preventing cancer
US20240058344A1 (en) 2020-12-18 2024-02-22 Cornell University Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
AU2021409394A1 (en) 2020-12-21 2023-07-27 Cornell University Peptide-linked drug delivery system
US20240132480A1 (en) 2021-01-08 2024-04-25 Cornell University Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
WO2022238507A1 (en) 2021-05-11 2022-11-17 Awakn Ls Europe Holdings Limited Therapeutic aminoindane compounds and compositions
WO2022248621A1 (en) 2021-05-25 2022-12-01 Awakn Ls Europe Holdings Limited Ketamine the treatment of behavioural addictions
US11541071B1 (en) 2021-12-16 2023-01-03 Ascletis BioScience Co., Ltd Nucleoside derivatives and methods of use thereof
WO2023139163A1 (en) 2022-01-19 2023-07-27 Awakn Ls Europe Holdings Limited 1,3-benzodioxole esters and their therapeutic use
WO2023156565A1 (en) 2022-02-16 2023-08-24 Awakn Ls Europe Holdings Limited Bridged ring compounds and their therapeutic use as cns agents
TW202400185A (en) 2022-03-02 2024-01-01 美商基利科學股份有限公司 Compounds and methods for treatment of viral infections
WO2023250157A1 (en) 2022-06-24 2023-12-28 Cornell University Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
WO2024013209A1 (en) 2022-07-13 2024-01-18 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof

Family Cites Families (303)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2007275A (en) 1933-01-09 1935-07-09 Elizabeth Q Kendall Ingot stripper
US2759300A (en) 1954-08-11 1956-08-21 Pest Control Ltd Method and means for introducing a predetermined amount of a poisonous material beneath the surface of the soil
USRE29835E (en) 1971-06-01 1978-11-14 Icn Pharmaceuticals 1,2,4-Triazole nucleosides
US3798209A (en) 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
US3852267A (en) 1972-08-04 1974-12-03 Icn Pharmaceuticals Phosphoramidates of 3{40 ,5{40 -cyclic purine nucleotides
JPS5116273A (en) 1974-07-31 1976-02-09 Hitachi Ltd DATSUSHOSOCHINIOKERU NH3 CHUNYURYONO SEIGYOHO
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
NL8403224A (en) 1984-10-24 1986-05-16 Oce Andeno Bv DIOXAPHOSPHORINANS, THEIR PREPARATION AND THE USE FOR SPLITTING OF OPTICALLY ACTIVE COMPOUNDS.
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
GB8719367D0 (en) 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
WO1989002733A1 (en) 1987-09-22 1989-04-06 The Regents Of The University Of California Liposomal nucleoside analogues for treating aids
IL91664A (en) * 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US6132763A (en) 1988-10-20 2000-10-17 Polymasc Pharmaceuticals Plc Liposomes
US5705363A (en) 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5026687A (en) * 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
AU660925B2 (en) 1990-04-06 1995-07-13 Genelabs Technologies, Inc. Hepatitis C virus epitopes
WO1991016920A1 (en) 1990-05-07 1991-11-14 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
EP0531452A4 (en) 1990-05-29 1993-06-09 Vical, Inc. Synthesis of glycerol di- and triphosphate derivatives
ES2083580T3 (en) 1990-06-13 1996-04-16 Arnold Glazier PHOSPHORIC DRUGS.
US6060080A (en) * 1990-07-16 2000-05-09 Daiichi Pharmaceutical Co., Ltd. Liposomal products
JP2599492B2 (en) 1990-08-21 1997-04-09 第一製薬株式会社 Manufacturing method of liposome preparation
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5256641A (en) 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5149794A (en) * 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5157027A (en) 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
CA2112803A1 (en) 1991-07-12 1993-01-21 Karl Y. Hostetler Antiviral liponucleosides: treatment of hepatitis b
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
TW224053B (en) 1991-09-13 1994-05-21 Paul B Chretien
US5676942A (en) 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
US5405598A (en) * 1992-02-24 1995-04-11 Schinazi; Raymond F. Sensitizing agents for use in boron neutron capture therapy
JP3102945B2 (en) 1992-02-27 2000-10-23 財団法人野田産業科学研究所 Hepatitis treatment
US5610054A (en) 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
US5256798A (en) 1992-06-22 1993-10-26 Eli Lilly And Company Process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates
US5426183A (en) 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
DE69311000T2 (en) 1992-06-22 1997-11-27 Lilly Co Eli Process for the preparation of 1-halogen-2-deoxy-2,2-difluoro-D-ribofuranosyl derivatives enriched with alpha anomers
US5301508A (en) 1992-08-14 1994-04-12 Rubbermaid Incorporated Thermoelectric portable container
TW356472B (en) * 1992-09-01 1999-04-21 Lilly Co Eli A process for anomerizing nucleosides
GB9226729D0 (en) 1992-12-22 1993-02-17 Wellcome Found Therapeutic combination
DE69419244T2 (en) * 1993-02-24 1999-10-14 Jui H Wang COMPOSITIONS AND METHODS FOR THE USE OF REACTIVE ANTIVIRAL POLYMERS
US6180134B1 (en) * 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
CA2162574A1 (en) 1993-05-12 1994-11-24 Karl Y. Hostetler Acyclovir derivatives for topical use
AU688344B2 (en) 1993-07-19 1998-03-12 Mitsubishi-Tokyo Pharmaceuticals, Inc. Hepatitis C virus proliferation inhibitor
US7375198B2 (en) * 1993-10-26 2008-05-20 Affymetrix, Inc. Modified nucleic acid probes
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
ES2174915T3 (en) 1993-11-10 2002-11-16 Enzon Inc IMPROVED CONJUGATION PRODUCTS OF AN INTERFERON WITH A POLYMER.
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
AU6550394A (en) 1994-03-11 1995-09-25 Isis Pharmaceuticals, Inc. Novel pyrimidine nucleosides
DE4415539C2 (en) 1994-05-03 1996-08-01 Osama Dr Dr Med Omer Plants with virustatic and antiviral effects
CA2192950A1 (en) * 1994-06-22 1995-12-28 Danny P.C. Mcgee Novel method of preparation of known and novel 2'-modified nucleosides by intramolecular nucleophilic displacement
DE4432623A1 (en) 1994-09-14 1996-03-21 Huels Chemische Werke Ag Process for bleaching aqueous surfactant solutions
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5696277A (en) 1994-11-15 1997-12-09 Karl Y. Hostetler Antiviral prodrugs
US6391859B1 (en) * 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
KR100330602B1 (en) 1995-02-01 2002-08-22 레스프로텍트 게엠베하 Use of 5' substtuted nucleosides to provide resistance in cytostatic treatment and medicaments containing said nucleosides
GB9505025D0 (en) * 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
DE19514523A1 (en) 1995-04-12 1996-10-17 Schering Ag New cytosine and cytidine derivatives
AU719122B2 (en) 1995-09-27 2000-05-04 Emory University Recombinant hepatitis C virus RNA replicase
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5767097A (en) * 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
GB9602028D0 (en) * 1996-02-01 1996-04-03 Amersham Int Plc Nucleoside analogues
US5980884A (en) 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
WO1997032018A2 (en) 1996-02-29 1997-09-04 Immusol, Inc. Hepatitis c virus ribozymes
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5830905A (en) 1996-03-29 1998-11-03 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5990276A (en) 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
GB9609932D0 (en) 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
US5891874A (en) 1996-06-05 1999-04-06 Eli Lilly And Company Anti-viral compound
US5837257A (en) 1996-07-09 1998-11-17 Sage R&D Use of plant extracts for treatment of HIV, HCV and HBV infections
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
IL129126A0 (en) * 1996-10-16 2000-02-17 Icn Pharmaceuticals Monocyclic l-nucleosides analogs and uses thereof
US6455690B1 (en) * 1996-10-16 2002-09-24 Robert Tam L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine
US6509320B1 (en) * 1996-10-16 2003-01-21 Icn Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses thereof
SK48199A3 (en) * 1996-10-16 2000-01-18 Icn Pharmaceuticals Purine l-nucleosides, analogs and uses thereof
PL194025B1 (en) 1996-10-18 2007-04-30 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
IL119833A (en) 1996-12-15 2001-01-11 Lavie David Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
CZ293248B6 (en) 1997-06-30 2004-03-17 Merz Pharma Gmbh & Co. Kgaa 1-Aminocycohexane derivative and pharmaceutical composition based thereon
DE69827956T2 (en) 1997-08-11 2005-04-14 Boehringer Ingelheim (Canada) Ltd., Laval PEPTIDE ANALOGUE WITH INHIBITORAL EFFECT ON HEPATITIS C
DE69810822T2 (en) 1997-09-21 2003-11-20 Schering Corp Combination therapy for the removal of detectable HCV-RNA in patients with chronic hepatitis C infection
US6703374B1 (en) * 1997-10-30 2004-03-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleosides for imaging and treatment applications
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
ATE212661T1 (en) 1998-01-23 2002-02-15 Newbiotics Inc THERAPEUTIC SUBSTANCES OBTAINED BY ENZYME CATALYSIS.
KR100954390B1 (en) 1998-02-25 2010-04-26 에모리 유니버시티 2'-Fluoronucleosides
US6787305B1 (en) 1998-03-13 2004-09-07 Invitrogen Corporation Compositions and methods for enhanced synthesis of nucleic acid molecules
CA2326535A1 (en) 1998-03-27 1999-10-07 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
AU3376699A (en) * 1998-03-31 1999-10-18 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
KR100694345B1 (en) 1998-05-15 2007-03-12 쉐링 코포레이션 Pharmaceutical composition comprising ribavirin and interferon alpha for antiviral treatment naive patients having chronic hepatitis c infection
EP1087778B1 (en) 1998-06-08 2005-10-26 F. Hoffmann-La Roche Ag Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
DE69925918T2 (en) 1998-07-27 2006-05-11 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. DIKETIC ACID DERIVATIVES AS POLYMERASES INHIBITORS
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
ES2255295T3 (en) 1998-08-10 2006-06-16 Idenix (Cayman) Limited 2'-DEOXI-BETA-L-NUCLEOSIDS FOR THE TREATMENT OF HEPATITIS B.
AR021876A1 (en) 1998-12-18 2002-08-07 Schering Corp COMBINATION THERAPY FOR HCV INDUCTION OF RIBAVIRINA - INTERFERON ALFA PEGILADO
AU775601B2 (en) 1999-07-22 2004-08-05 Celmed Oncology (Usa) Inc. Enzyme catalyzed therapeutic activation
KR20020091829A (en) 1999-07-30 2002-12-06 애보트 게엠베하 운트 콤파니 카게 2-Pyrazolin-5-ones
CA2389745C (en) 1999-11-04 2010-03-23 Shire Biochem Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
CN1919858A (en) * 1999-11-12 2007-02-28 法玛赛特有限公司 Synthesis of 2'-deoxy-l-nucleosides
US6495677B1 (en) 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
SK11922002A3 (en) 2000-02-18 2003-06-03 Shire Biochem Inc. Method for the treatment or prevention of flavivirus infections using nucleoside analogues
ES2319732T3 (en) 2000-04-13 2009-05-12 Pharmasset, Inc. DERIVATIVES OF NUCLEOSIDE 3'- OR 2'-HYDROXIMETHYL REPLACED FOR THE TREATMENT OF VIRAL INFECTIONS.
EP1282632A1 (en) 2000-04-20 2003-02-12 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1736478B1 (en) 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Methods and compositions for treating flaviviruses and pestiviruses
EA005890B1 (en) 2000-05-26 2005-06-30 Айденикс (Кайман) Лимитед Methods for treating hepatitis delta virus infection with beta-l-2'-deoxy-nucleosides
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
FR2810322B1 (en) * 2000-06-14 2006-11-10 Pasteur Institut COMBINATORY PRODUCTION OF NUCLEOTIDE AND NUCLEOTIDE ANALOGUES (XiTP)
MY141594A (en) 2000-06-15 2010-05-14 Novirio Pharmaceuticals Ltd 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
US6815542B2 (en) 2000-06-16 2004-11-09 Ribapharm, Inc. Nucleoside compounds and uses thereof
UA72612C2 (en) * 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
ES2536972T5 (en) 2000-07-21 2022-04-06 Gilead Sciences Inc Phosphonate nucleotide analog prodrugs and methods for selecting and preparing the same
EP1301527A2 (en) 2000-07-21 2003-04-16 Corvas International, Inc. Peptides as ns3-serine protease inhibitors of hepatitis c virus
AR029851A1 (en) 2000-07-21 2003-07-16 Dendreon Corp NEW PEPTIDES AS INHIBITORS OF NS3-SERINA PROTEASA DEL VIRUS DE HEPATITIS C
MXPA03000626A (en) 2000-07-21 2004-07-30 Schering Corp Novel peptides as ns3-serine protease inhibitors of hepatitis c virus.
AR034127A1 (en) 2000-07-21 2004-02-04 Schering Corp IMIDAZOLIDINONES AS INHIBITORS OF NS3-SERINA PROTEASA OF THE HEPATITIS C VIRUS, PHARMACEUTICAL COMPOSITION, A METHOD FOR THEIR PREPARATION, AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
AR039558A1 (en) * 2000-08-21 2005-02-23 Inspire Pharmaceuticals Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION
US6897201B2 (en) * 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
PT1411954E (en) * 2000-10-18 2011-03-16 Pharmasset Inc Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
WO2002032414A2 (en) 2000-10-18 2002-04-25 Schering Corporation Ribavirin-pegylated interferon alfa hcv combination therapy
US6555677B2 (en) 2000-10-31 2003-04-29 Merck & Co., Inc. Phase transfer catalyzed glycosidation of an indolocarbazole
BR0115447A (en) 2000-11-20 2005-10-18 Bristol Myers Squibb Co Hepatitis C Tripeptide Inhibitors
KR20030091946A (en) 2000-12-12 2003-12-03 쉐링 코포레이션 Diaryl peptides as NS3-serine protease inhibitors of hepatitis C virus
WO2002048157A2 (en) 2000-12-13 2002-06-20 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
WO2002048116A2 (en) 2000-12-13 2002-06-20 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
AU2002232660A1 (en) 2000-12-15 2002-06-24 Pharmasset Ltd. Antiviral agents for treatment of flaviviridae infections
EP1539188B1 (en) 2001-01-22 2015-01-07 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US7105499B2 (en) * 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
GB0112617D0 (en) 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
WO2003000713A1 (en) 2001-06-21 2003-01-03 Glaxo Group Limited Nucleoside compounds in hcv
JP4455056B2 (en) 2001-07-11 2010-04-21 バーテックス ファーマシューティカルズ インコーポレイテッド Cross-linked bicyclic serine protease inhibitor
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US6962991B2 (en) 2001-09-12 2005-11-08 Epoch Biosciences, Inc. Process for the synthesis of pyrazolopyrimidines
WO2003022861A1 (en) 2001-09-13 2003-03-20 Bristol-Myers Squibb Company Process for the preparation of rebeccamycin and analogs thereof
WO2003024461A1 (en) 2001-09-20 2003-03-27 Schering Corporation Hcv combination therapy
JP2005504087A (en) * 2001-09-28 2005-02-10 イデニクス（ケイマン）リミテツド Methods and compositions for the treatment of hepatitis C virus using 4 'modified nucleosides
WO2003037895A1 (en) 2001-11-02 2003-05-08 Glaxo Group Limited 4-(6-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
GB0129945D0 (en) 2001-12-13 2002-02-06 Mrc Technology Ltd Chemical compounds
CA2470255C (en) 2001-12-14 2012-01-17 Kyoichi A. Watanabe N4-acylcytosine nucleosides for treatment of viral infections
AU2002353165A1 (en) 2001-12-17 2003-06-30 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
JP2005514401A (en) * 2001-12-21 2005-05-19 マイクロロジックス　バイオテック，インコーポレイテッド Antiviral 7-deaza L-nucleoside
WO2003062256A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
EP1476169B1 (en) * 2002-02-13 2013-03-20 Merck Sharp & Dohme Corp. Inhibiting orthopoxvirus replication with nucleoside compounds
US7285658B2 (en) * 2002-02-28 2007-10-23 Biota, Inc. Nucleotide mimics and their prodrugs
CA2477795A1 (en) 2002-02-28 2003-09-12 Kandasamy Sakthivel Nucleoside 5'-monophosphate mimics and their prodrugs
US20040014108A1 (en) * 2002-05-24 2004-01-22 Eldrup Anne B. Oligonucleotides having modified nucleoside units
ES2304511T3 (en) 2002-06-04 2008-10-16 Schering Corporation PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE AS ANTIVIRAL AGENTS.
EP1511757B1 (en) 2002-06-07 2015-11-04 Universitair Medisch Centrum Utrecht New compounds for modulating the activity of exchange proteins directly activated by camp (epacs)
EP1515971A2 (en) 2002-06-17 2005-03-23 Merck & Co., Inc. Carbocyclic nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
AU2003248708A1 (en) 2002-06-17 2003-12-31 Isis Pharmaceuticals, Inc. Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
EP1551421A2 (en) 2002-06-21 2005-07-13 Merck & Co. Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US20060234962A1 (en) 2002-06-27 2006-10-19 Olsen David B Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
AU2003247084B9 (en) 2002-06-28 2018-07-26 Centre National De La Recherche Scientifique Modified 2' and 3'-nucleoside prodrugs for treating flaviridae infections
CN101172992A (en) * 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections
AU2003263412A1 (en) 2002-06-28 2004-01-19 Centre National De La Recherche Scientifique (Cnrs) 1'-, 2'- and 3'- modified nucleoside derivatives for treating flaviviridae infections
MXPA04012802A (en) 2002-06-28 2005-04-19 Idenix Cayman Ltd 2aCOE-C-METHYL-3aCOE-O-L-VALINE ESTER RIBOFURANOSYL CYTIDINE FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS.
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
US7041690B2 (en) 2002-07-01 2006-05-09 Pharmacia & Upjohn Company, Llc Inhibitors of HCV NS5B polymerase
MXPA05000256A (en) 2002-07-01 2005-07-15 Upjohn Co Inhibitors of hcv ns5b polymerase.
US6973905B2 (en) 2002-07-01 2005-12-13 Cinetic Automation Corporation Valve lash adjustment apparatus and method
JP2005533108A (en) 2002-07-16 2005-11-04 メルク　エンド　カムパニー　インコーポレーテッド Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
EP1572709A3 (en) 2002-07-24 2005-11-23 PTC Therapeutics, Inc. Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
WO2004009020A2 (en) 2002-07-24 2004-01-29 Merck & Co., Inc. Pyrrolopyrimidine thionucleoside analogs as antivirals
JP2005538096A (en) * 2002-07-25 2005-12-15 マイジェニックス インコーポレイテッド Antiviral 7-deaza D-nucleosides and methods of use thereof
WO2004014852A2 (en) 2002-08-12 2004-02-19 Bristol-Myers Squibb Company Iminothiazolidinones as inhibitors of hcv replication
BR0314259A (en) * 2002-09-13 2005-07-26 Idenix Cayman Ltd ß-l-2'-deoxynucleotides for the treatment of resistant HBV strains and combination therapies
US20050215614A1 (en) 2002-10-15 2005-09-29 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
US20040229840A1 (en) 2002-10-29 2004-11-18 Balkrishen Bhat Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
WO2004041201A2 (en) 2002-11-01 2004-05-21 Viropharma Incorporated Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
MXPA05005192A (en) 2002-11-15 2005-09-08 Idenix Cayman Ltd 2aCOE-BRANCHED NUCLEOSIDES AND FLAVIVIRIDAE.
TWI332507B (en) * 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
CA2509687C (en) * 2002-12-12 2012-08-14 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
AU2003225705A1 (en) 2003-03-07 2004-09-30 Ribapharm Inc. Cytidine analogs and methods of use
KR20060008297A (en) 2003-03-20 2006-01-26 마이크로 바이올로지카 퀴미카 이 파마슈티카 리미티드 METHODS OF MANUFACTURE OF 2'-DEOXY-beta-L-NUCLEOSIDES
US7173004B2 (en) 2003-04-16 2007-02-06 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
SG182849A1 (en) 2003-04-25 2012-08-30 Gilead Sciences Inc Antiviral phosphonate analogs
US20050261237A1 (en) 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
EA200501676A1 (en) 2003-04-25 2006-04-28 Джилид Сайэнс, Инк. PHOSPHONATE-CONTAINING KINASE INHIBITORS (OPTIONS), METHOD FOR THEIR RECEIVING, PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL FORM ON THEIR BASIS AND METHOD FOR INHIBING KINASE IN MOLOPYTIC TREATMENT THEM
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
EP1617848A2 (en) 2003-04-25 2006-01-25 Gilead Sciences, Inc. Anti-cancer phosphonate conjugates
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
WO2004096210A1 (en) 2003-05-01 2004-11-11 Glaxo Group Limited Acylated indoline and tetrahydroquinoline derivatives as hcv inhibitors
US20040259934A1 (en) 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
EP1656093A2 (en) 2003-05-14 2006-05-17 Idenix (Cayman) Limited Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
CN100503628C (en) 2003-05-30 2009-06-24 法莫赛特股份有限公司 Modified fluorinated nucleoside analogues
US7507859B2 (en) 2003-06-16 2009-03-24 Fifth Base Llc Functional synthetic molecules and macromolecules for gene delivery
RU2243972C1 (en) 2003-06-26 2005-01-10 Государственный научный центр вирусологии и биотехнологии "Вектор" Nucleoside analog phosphoramidates as inhibitors of human immunodeficiency virus reproduction
RU2361875C2 (en) 2003-06-30 2009-07-20 Айденикс (Кайман) Лимитед SYNTHESIS OF β-L-2'-DESOXYNUCLEOSIDES
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
AU2004258750A1 (en) * 2003-07-25 2005-02-03 Centre National De La Recherche Scientifique -Cnrs Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis C
JP2007504152A (en) 2003-08-27 2007-03-01 ビオタ， インコーポレイテッド Novel tricyclic nucleosides or nucleotides as therapeutic agents
JP4685775B2 (en) 2003-09-18 2011-05-18 バーテックス ファーマシューティカルズ インコーポレイテッド Inhibitors of serine proteases, especially HCV NS3-NS4A protease
US7348389B2 (en) 2003-09-22 2008-03-25 E. I. Du Pont De Nemours And Company Method for achieving recoat adhesion over a fluorinated topcoat
US20050148534A1 (en) * 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
AP2287A (en) 2003-10-14 2011-10-31 Intermune Inc Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication.
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
MXPA06004680A (en) * 2003-10-27 2007-04-17 Genelabs Tech Inc Nucleoside compounds for treating viral infections.
US7026339B2 (en) * 2003-11-07 2006-04-11 Fan Yang Inhibitors of HCV NS5B polymerase
TW200528459A (en) 2004-01-06 2005-09-01 Achillion Pharmaceuticals Inc Azabenzofuran substituted thioureas; inhibitors of viral replication
CN1913778A (en) 2004-01-28 2007-02-14 默克公司 Aminocyclopentyl pyridopyrazinone modulators of chemokine receptor activity
EP1718150A1 (en) 2004-02-25 2006-11-08 The Government of the United States of America, represented by the Secretary, Department of Health and Human Services Methylation inhibitor compounds
WO2005087788A2 (en) 2004-03-04 2005-09-22 The Regents Of The University Of California Methods for preparation of nucleoside phosphonate esters
AU2005228894B9 (en) 2004-03-30 2011-10-13 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
GB0408995D0 (en) 2004-04-22 2004-05-26 Glaxo Group Ltd Compounds
JP5055564B2 (en) 2004-06-15 2012-10-24 メルク・シャープ・エンド・ドーム・コーポレイション C-purine nucleoside analogues as inhibitors of RNA-dependent RNA viral polymerase
WO2006000922A2 (en) 2004-06-23 2006-01-05 Idenix (Cayman) Limited 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
US20070265222A1 (en) 2004-06-24 2007-11-15 Maccoss Malcolm Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection
US7217523B2 (en) * 2004-07-02 2007-05-15 Regents Of The University Of Minnesota Nucleoside phosphoramidates and nucleoside phosphoramidases
ES2386005T3 (en) 2004-07-21 2012-08-07 Gilead Pharmasset Llc Preparation of 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and alkyl substituted purines and their derivatives
CN101023094B (en) 2004-07-21 2011-05-18 法莫赛特股份有限公司 Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
EP2258376B1 (en) * 2004-07-27 2019-02-27 Gilead Sciences, Inc. Phosphonate analogs of HIV inhibitor compounds
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7348425B2 (en) * 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
EP1794172B1 (en) * 2004-08-23 2009-07-15 F.Hoffmann-La Roche Ag Antiviral 4'-azido-nucleosides
BRPI0514591A (en) * 2004-08-23 2008-06-17 Hoffmann La Roche heterocyclic antiviral compounds
WO2006029081A2 (en) 2004-09-02 2006-03-16 Neopharm, Inc. Nucleoside-lipid conjugates, their method of preparation and uses thereof
KR101177590B1 (en) * 2004-09-14 2012-08-27 파마셋 인코포레이티드 Preparation of 2'-fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
CA2581523A1 (en) 2004-09-24 2006-04-06 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses, pestiviruses and hepacivirus
AU2005288858B2 (en) 2004-09-30 2011-04-21 Janssen R&D Ireland HCV inhibiting bi-cyclic pyrimidines
JP2008517912A (en) 2004-10-21 2008-05-29 メルク エンド カムパニー インコーポレーテッド Fluorinated pyrrolo [2,3-d] pyrimidine nucleosides for the treatment of RNA-dependent RNA viral infections
NZ555441A (en) 2004-10-29 2010-12-24 Biocryst Pharm Inc Therapeutic furopyrimidines and thienopyrimidines
US20060116557A1 (en) 2004-11-30 2006-06-01 Alere Medical Incorporated Methods and systems for evaluating patient data
CA2589935A1 (en) 2004-12-09 2006-06-15 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
WO2006065590A2 (en) 2004-12-16 2006-06-22 Xtl Biopharmaceuticals Inc. Pyridine and pyrimidine antiviral compositions
WO2006063717A2 (en) * 2004-12-16 2006-06-22 Febit Biotech Gmbh Polymerase-independent analysis of the sequence of polynucleotides
EP1674104A1 (en) 2004-12-24 2006-06-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Uridine derivatives as antiviral drugs against a flaviviridae, especially HCV
WO2006093801A1 (en) 2005-02-25 2006-09-08 Abbott Laboratories Thiadiazine derivatives useful as anti-infective agents
BRPI0607769A2 (en) * 2005-02-28 2009-10-06 Genelabs Tech Inc nucleoside-tricyclic prodrugs for the treatment of viral infections
US20060199738A1 (en) 2005-03-04 2006-09-07 Sumitomo Chemical Company, Limited Herbicidal composition
JP2008534479A (en) 2005-03-25 2008-08-28 テイボテク・フアーマシユーチカルズ・リミテツド Heterobicyclic inhibitors of HCV
AR056327A1 (en) 2005-04-25 2007-10-03 Genelabs Tech Inc NUCLEOSID COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
TW200716631A (en) 2005-05-12 2007-05-01 Tibotec Pharm Ltd Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof
AR056347A1 (en) 2005-05-12 2007-10-03 Tibotec Pharm Ltd USE OF PTERIDINE COMPOUNDS TO MANUFACTURE PHARMACEUTICAL MEDICINES AND COMPOSITIONS
WO2007027248A2 (en) 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
US20060293752A1 (en) 2005-06-27 2006-12-28 Missoum Moumene Intervertebral disc prosthesis and associated methods
EP2305695A3 (en) 2005-07-25 2011-07-27 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
ES2373685T3 (en) 2005-07-29 2012-02-07 Tibotec Pharmaceuticals MACROCYCLIC INHIBITORS OF HEPATITIS VIRUS C.
JP5426164B2 (en) 2005-07-29 2014-02-26 ヤンセン・アールアンドデイ・アイルランド Macrocyclic inhibitor of hepatitis C virus
MY139988A (en) 2005-07-29 2009-11-30 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis c virus
AU2006274861B2 (en) 2005-07-29 2012-11-08 Medivir Ab Macrocyclic inhibitors of hepatitis C virus
PE20070211A1 (en) 2005-07-29 2007-05-12 Medivir Ab MACROCYCLIC COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS
JP2009504704A (en) * 2005-08-15 2009-02-05 エフ．ホフマン−ラ ロシュ アーゲー Antiviral 4'-substituted pronucleotide phosphoramidate
GB0519478D0 (en) 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519488D0 (en) 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
RU2422454C2 (en) * 2005-12-09 2011-06-27 Ф. Хоффманн-Ля Рош Аг Antiviral nucleosides
BRPI0619733A2 (en) 2005-12-12 2011-10-11 Genelabs Tech Inc n- (6-membered aromatic ring) -amido antiviral compounds
ATE541844T1 (en) 2005-12-21 2012-02-15 Abbott Lab ANTIVIRAL COMPOUNDS
GB0602046D0 (en) 2006-02-01 2006-03-15 Smithkline Beecham Corp Compounds
WO2007092000A1 (en) 2006-02-06 2007-08-16 Bristol-Myers Squibb Company Inhibitors of hcv replication
CA2637879A1 (en) 2006-02-14 2007-08-23 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
WO2007093901A1 (en) 2006-02-17 2007-08-23 Pfizer Limited 3 -deazapurine derivatives as tlr7 modulators
US8895531B2 (en) 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
CN101490054B (en) 2006-05-25 2012-05-16 百时美施贵宝公司 Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
ES2546378T3 (en) 2006-07-07 2015-09-23 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutic agents
EP1881001A1 (en) 2006-07-20 2008-01-23 Tibotec Pharmaceuticals Ltd. HCV NS-3 serine protease inhibitors
BRPI0719174A2 (en) 2006-10-10 2017-06-13 Hoffmann La Roche preparation of ribofuranosyl nucleoside pyrimidines
PL216525B1 (en) 2006-10-17 2014-04-30 Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk 5'-0-[(N-acyl) amidophosphate] - and 5'-0- [(N-acyl) amidothiophosphate]- and 5'-0- [N-acyl) amidodithiophosphate] and 5'-0- [N-acyl) amidoselenophosphate] - nucleosides and method for their manufacture
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US8148349B2 (en) 2006-12-20 2012-04-03 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
CA2673649A1 (en) * 2007-01-05 2008-07-17 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
WO2008104408A2 (en) 2007-02-27 2008-09-04 K. U. Leuven Research & Development Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
GB0709791D0 (en) 2007-05-22 2007-06-27 Angeletti P Ist Richerche Bio Antiviral agents
CN101108870A (en) 2007-08-03 2008-01-23 冷一欣 Process for preparation of nucleoside phosphoric acid ester compound and application thereof
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
JP5238939B2 (en) 2007-11-07 2013-07-17 三菱化学株式会社 Long fiber reinforced composite resin composition and molded product
US20090176732A1 (en) 2007-12-21 2009-07-09 Alios Biopharma Inc. Protected nucleotide analogs
US8227431B2 (en) 2008-03-17 2012-07-24 Hetero Drugs Limited Nucleoside derivatives
WO2009142822A2 (en) 2008-03-26 2009-11-26 Alnylam Pharmaceuticals, Inc. 2-f modified rna interference agents
US8415321B2 (en) 2008-04-15 2013-04-09 Raymond F. Schinazi Nucleoside derivatives for treatment of Caliciviridae infections, including Norovirus infections
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010009121A2 (en) 2008-07-15 2010-01-21 University Of Florida Research Foundation, Inc. Colon stem cells associated with colitis and colorectal cancer and methods of use
EP2346329B1 (en) 2008-10-09 2013-08-21 Anadys Pharmaceuticals, Inc. A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
AU2009329867B2 (en) 2008-12-23 2015-01-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
TW201031675A (en) 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
CA2748792A1 (en) 2009-01-07 2010-07-15 Samuel Earl Hopkins Combination of a cyclosporine derivative and nucleosides for treating hcv
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (en) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
HUE026235T2 (en) 2010-03-31 2016-06-28 Gilead Pharmasset Llc Crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1-(2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
US20120107278A1 (en) 2010-10-29 2012-05-03 Pharmasset, Inc. Abbreviated hcv therapy for hcv infected patients with il28b c/c genotype
US20130109647A1 (en) 2011-10-31 2013-05-02 Gilead Pharmasset Llc Methods and compositions for treating hepatitis c virus
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus

Also Published As

Publication number Publication date
CY2014047I1 (en) 2017-07-12
US8957046B2 (en) 2015-02-17
SI2801580T1 (en) 2024-01-31
US7964580B2 (en) 2011-06-21
RU2478104C2 (en) 2013-03-27
TW200904453A (en) 2009-02-01
ES2963716T3 (en) 2024-04-01
KR20150008929A (en) 2015-01-23
KR20100016041A (en) 2010-02-12
US8334270B2 (en) 2012-12-18
CN109970818A (en) 2019-07-05
US20140315852A1 (en) 2014-10-23
SG2014011704A (en) 2014-05-29
AU2008232827B2 (en) 2012-08-16
EP2826784B1 (en) 2019-06-26
EP2801580A1 (en) 2014-11-12
WO2008121634A2 (en) 2008-10-09
JP6377781B2 (en) 2018-08-22
US9585906B2 (en) 2017-03-07
CN109456373A (en) 2019-03-12
NO2014029I1 (en) 2014-12-01
KR101525293B1 (en) 2015-06-03
CN104402955A (en) 2015-03-11
PL2203462T3 (en) 2015-01-30
RU2018103329A3 (en) 2021-05-24
DK2203462T3 (en) 2014-08-11
SI2826784T1 (en) 2019-10-30
CA2682230C (en) 2014-04-22
EP2826784A1 (en) 2015-01-21
CN109776637B (en) 2023-04-18
HRP20140667T1 (en) 2014-10-10
HUS1400059I1 (en) 2017-07-28
PH12014502771A1 (en) 2015-10-26
NZ579880A (en) 2012-05-25
JP2016023187A (en) 2016-02-08
US10183037B2 (en) 2019-01-22
NL300704I1 (en) 2015-12-29
EP2203462A2 (en) 2010-07-07
ZA200906647B (en) 2013-06-26
IL217228A0 (en) 2012-01-31
LTPA2014040I1 (en) 2021-08-10
EP2801580B1 (en) 2023-09-13
IL217228A (en) 2013-08-29
US11642361B2 (en) 2023-05-09
EP2203462B1 (en) 2014-05-21
NO2014029I2 (en) 2014-11-18
CN101918425B (en) 2023-05-02
CA2682230A1 (en) 2008-10-09
FR14C0082I1 (en) 2014-12-26
JP2015024998A (en) 2015-02-05
IL222810A0 (en) 2012-12-31
CN101918425A (en) 2010-12-15
CN109970830A (en) 2019-07-05
RU2012152811A (en) 2014-06-20
US20140045783A1 (en) 2014-02-13
US20100016251A1 (en) 2010-01-21
CY2014047I2 (en) 2017-07-12
BRPI0809654A2 (en) 2015-04-22
US8580765B2 (en) 2013-11-12
US20130029929A1 (en) 2013-01-31
LTC2203462I2 (en) 2021-08-25
SG179445A1 (en) 2012-04-27
CN116731099A (en) 2023-09-12
JP2018197245A (en) 2018-12-13
JP5539419B2 (en) 2014-07-02
PT2801580T (en) 2023-12-06
BRPI0823519A2 (en) 2015-10-27
KR101432860B1 (en) 2014-08-26
US8735372B2 (en) 2014-05-27
US20180000855A1 (en) 2018-01-04
IL201239A (en) 2013-03-24
US8906880B2 (en) 2014-12-09
HK1206033A1 (en) 2015-12-31
JP5774749B2 (en) 2015-09-09
US20150231166A1 (en) 2015-08-20
US20210196741A1 (en) 2021-07-01
JP2014196305A (en) 2014-10-16
EP4282482A2 (en) 2023-11-29
JP2017132754A (en) 2017-08-03
TWI357332B (en) 2012-02-01
RU2009139968A (en) 2011-05-10
ES2492470T3 (en) 2014-09-09
SI2203462T1 (en) 2014-09-30
EP2933260A1 (en) 2015-10-21
JP5318085B2 (en) 2013-10-16
US20110257122A1 (en) 2011-10-20
MX2009010401A (en) 2009-11-10
US20140288020A1 (en) 2014-09-25
RU2651892C2 (en) 2018-04-24
KR101527701B1 (en) 2015-06-09
NZ599206A (en) 2013-08-30
ZA201200310B (en) 2013-05-29
RU2651892C3 (en) 2020-01-21
HK1206034A1 (en) 2015-12-31
CL2008000902A1 (en) 2008-11-07
WO2008121634A3 (en) 2010-05-20
EP2792680A1 (en) 2014-10-22
US20240139227A1 (en) 2024-05-02
KR20120034801A (en) 2012-04-12
CN116731098A (en) 2023-09-12
CN109776637A (en) 2019-05-21
JP2010532747A (en) 2010-10-14
JP2020100617A (en) 2020-07-02
JP2012121903A (en) 2012-06-28
AU2008232827A1 (en) 2008-10-09
EP2824109A1 (en) 2015-01-14
PL2826784T3 (en) 2019-11-29
PT2203462E (en) 2014-08-29
DE202008018643U1 (en) 2017-03-16
NL300704I2 (en) 2015-12-29
RU2018103329A (en) 2019-08-05
AR066898A1 (en) 2009-09-23
PT2826784T (en) 2019-09-12
PL2801580T3 (en) 2024-02-12
US20140187511A1 (en) 2014-07-03
MY147409A (en) 2012-11-30
CY1115488T1 (en) 2017-01-04
EP4282482A3 (en) 2024-01-17
ES2745462T3 (en) 2020-03-02
CO6260023A2 (en) 2011-03-22
LU92600I2 (en) 2015-11-24
IL201239A0 (en) 2010-05-31
US9085573B2 (en) 2015-07-21
AU2008232827C1 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
FR14C0082I2 (en) NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS
BR112012007122A2 (en) nucleoside phosphoramidate derivatives
IL213698A0 (en) Nucleoside phosphoramidates
BRPI0922508A2 (en) Nucleoside Analogs
BRPI0819797A2 (en) antiviral nucleoside compounds
DK2114980T3 (en) ANTIVIRAL Nucleoside Analogs
ATE554776T1 (en) ANTIVIRAL PHOSPHINATE COMPOUNDS
HRP20140223T1 (en) Dolutegravir prodrugs
DK1896040T3 (en) Phosphoramidate alkylator prodrugs
ZA201008829B (en) Nucleoside cyclicphosphates
BRPI0818380A2 (en) HERBICIDE-PROTECTOR COMBINATION
DK2511282T3 (en) URACYLSPIROOXETANE NUCLEOSIDES
BRPI0813995A2 (en) Shielding Arrangement
BR112012004105A2 (en) bisphosphonate prodrugs
BRPI0818249A2 (en) Nucleoside Production Method
BRPI0912820A2 (en) acetaminophen hepatoprotective agent prodrugs
BRPI1014802A2 (en) tryptolide prodrugs.
BRPI0807984A2 (en) DISTRIBUTION UNIT
DE112008002906A5 (en) paneling
TH0801001634A (en) Prodrugs Nucleoside Phosphoramidate
AU2014215983B2 (en) Nucleoside phosphoramidate prodrugs
FR2924209B1 (en) DEFENSE POLYBATON
TH94756B (en) Antiviral phosphinate compounds
UA13873S (en) PANELING
BRPI0720356A2 (en) STATUS ACCOMMODATION ARRANGEMENT